Depixus Overview

  • Founded
  • 2012

Founded
  • Status
  • Private

  • Employees
  • 63

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $34.9M

  • Investors
  • 8

Depixus General Information

Description

Developer of a single molecule genetic and epigenetic sequencing technology intended to offer extraction of genetic and epigenetic information from single molecules of DNA and RNA. The company's SIMDEQ (SIngle-molecule Magnetic DEtection and Quantification) technology permits a full genome or genomic region to be analyzed quickly and easily on a single integrated platform, with the investigator to specify the level of sequence and epigenetic detail required, enabling doctors with simple sample-preparation, sequential DNA fingerprinting, full-sequencing and epityping to avail a fast time-to-result.

Contact Information

Website
www.depixus.com
Formerly Known As
PicoSeq
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Devices and Supplies
Other Healthcare Technology Systems
Primary Office
  • 3-5 Impasse Reille
  • 75014 Paris
  • France
+33 09 00 00 00 00

Depixus Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Depixus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 15-Dec-2021 $34.9M 000.00 000.00 Completed Generating Revenue
6. Grant 01-May-2019 00.000 00.000 Completed Generating Revenue
5. Grant 00000 00.000 Completed Generating Revenue
4. Later Stage VC 31-Dec-2018 00.000 00.000 000.00 Completed Generating Revenue
3. Later Stage VC 29-Mar-2018 00.000 00.000 00.000 Completed Generating Revenue
2. Seed Round 04-Sep-2017 $2.33M $2.33M 00.000 Completed Generating Revenue
1. Accelerator/Incubator 26-Nov-2013 Completed Generating Revenue
To view Depixus’s complete valuation and funding history, request access »

Depixus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.00
To view Depixus’s complete cap table history, request access »

Depixus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a single molecule genetic and epigenetic sequencing technology intended to offer extraction of genetic and
Drug Discovery
Paris, France
63 As of 2022
000.00
00.00 0000-00-00
00000000000 000.00

000000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000000000000
South San Francisco, CA
00 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00

000 00

e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offici
0000000000 000000000
London, United Kingdom
000 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Depixus Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Quantapore Venture Capital-Backed South San Francisco, CA 00 000.00 0000000000 0 000.00
000 00000000000 Venture Capital-Backed London, United Kingdom 000 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed San Diego, CA 00 0000 00000 00000
000000 00000000 00 Formerly VC-backed Oxford, United Kingdom 000 00.000 00000000 00.000
000000 00000 Corporate Backed or Acquired Carlsbad, CA 00 000000000000
You’re viewing 5 of 17 competitors. Get the full list »

Depixus Patents

Depixus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3686642-A1 Multichannel close-up imaging device Withdrawn 24-Jan-2019 0000000000 00
EP-3914949-A1 Multichannel close-up imaging device Pending 24-Jan-2019 0000000000
CA-3123151-A1 Method of nucleic acid enrichment using site-specific nucleases followed by capture Pending 12-Dec-2018 0000000000
AU-2019398707-A1 Method of nucleic acid enrichment using site-specific nucleases followed by capture Pending 12-Dec-2018 0000000000
EP-3837379-A1 Method of nucleic acid enrichment using site-specific nucleases followed by capture Pending 12-Dec-2018 C12Q1/6806
To view Depixus’s complete patent history, request access »

Depixus Executive Team (6)

Name Title Board Seat Contact Info
Gordon Hamilton Ph.D Co-Founder, President, Chief Executive Officer & Board Member
Stephen Allen Ph.D Chief Business Officer & Board Member
David Bensimon Ph.D Co-Founder
Jean-François Allemand Co-Founder
Vincent Croquette Co-Founder
You’re viewing 5 of 6 executive team members. Get the full list »

Depixus Board Members (9)

Name Representing Role Since
John Berriman Self Chairman 000 0000
Lachlan MacKinnon Lansdowne Partners Board Member 000 0000
Mark Chin Arix Bioscience Board Member 000 0000
Ronald Lindsay Ph.D Self Board Member 000 0000
Stephen Allen Ph.D Depixus Chief Business Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Depixus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Depixus Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
Lansdowne Partners Hedge Fund Minority 000 0000 000000 0
Horizon 2020 SME Instrument Government 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »